你可能會喜歡
📢 Calling all radiation oncologists! We’re launching a peer-reviewed, PubMed-indexed #radonc supplement in 2026, and are accepting submissions. ✨Introducing @brandonmancini of @bamfhealth and @UMich as our editor-at-large. 👉Find out how to submit and get published today:…
PFS was significantly improved when 177Lu-PNT2002 was added to stereotactic body radiotherapy for patients with oligorecurrent hormone-sensitive prostate cancer. hubs.li/Q03Wy7vH0 #pcsm #cancer #oncology
Use of PEG hydrogels significantly reduced radiation to the rectum without increasing dosage to other organs at risk in patients undergoing radical concurrent chemoradiotherapy for cervical cancer. hubs.li/Q03WycX10 #gyncsm #oncology #cancer
HRQOL scores were similar in patients who received a radical cystectomy vs bladder persevering therapy for non-muscle invasive bladder cancer. hubs.li/Q03Wx_Lq0 #NMIBC #blcsm #oncology
The FDA has granted traditional approval to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor. hubs.li/Q03WGSpH0 #lymsm #leusm #oncology | @FDAOncology
Subcutaneous toripalimab plus chemotherapy exhibited noninferior drug exposure compared with toripalimab injection in metastatic or recurrent nonsquamous NSCLC. hubs.li/Q03Wy0yR0 #NSCLC #lcsm #oncology
Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC. hubs.li/Q03WxXVW0 #pcsm #cancer #oncology
Final results from HERIZON-BTC-01 showed zanidatamab achieved a cORR of 41.3%, with a DOR of 14.9 months, in biliary tract cancer. hubs.li/Q03WxXSx0 #cancer #oncology #biliary
Updated 5-year results from the phase 2 JULIET trial showed that the ORR with tisa-cel was 53.0%, with 39.1% of patients having a best overall response of CR. Read the full article here: hubs.li/Q03WlDmj0 #lymsm #lymphoma #oncology
According to John Henson, MD, patients with ovarian, breast, endometrial, and colon cancers benefit the most from proactive hereditary analyses. Read the full conversation here: hubs.li/Q03WlJCv0 #btsm #cancer #oncology | @GACancerCenter
Beyond just the physical aspect of cancer treatment, the logistical, financial, and emotional burdens caused by treatment significantly impacts patients. We spoke with @GreenupRachel about these considerations. Read here: hubs.li/Q03WlFnG0 #bcsm #cancer #oncology
The number of oncologists qualified to treat the aging US population is declining! 🎙️ We spoke with the authors of the eye-opening study 🎥 Read the transcript here: hubs.li/Q03WlDWl0 #cancer #oncology | @MAccordino | @ASCO
FDA grants Priority Review for sonrotoclax in relapsed/refractory MCL (post-BTKi). Phase 1/2 data showed the BCL2 inhibitor met its ORR endpoint. Full data due at #ASH25. hubs.li/Q03Wlv9V0 #lymsm #MCL #Hematology #Oncology
The FDA has approved an updated label for cosibelimab-ipdl for adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are ineligible to receive curative surgery or radiation. hubs.li/Q03Wlp9w0 #cancer #oncology
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care, according to @guicorreiamd. Watch more here: hubs.li/Q03VT96p0 #lcsm #oncology #cancer
When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD, and Yesne Alici, MD, utilize several decision-making capacity techniques. Read more here: hubs.li/Q03VTbRs0 #cancer #oncology
“What we need are better treatments to control the [brain] tumor once it’s detected," said John Henson, MD. Watch here: hubs.li/Q03VT82N0 #btsm #cancer #oncology | @GACancerCenter
PAS-004 achieved positive PD, PK, and safety results in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1, or RAF mutation, or in those in which prior BRAF/MEK inhibition had failed patients. hubs.li/Q03VTckW0 #cancer #oncology
Priming strategies with olaparib, including the addition of durvalumab with or without low-dose cyclophosphamide, did not definitively improve efficacy outcomes vs olaparib monotherapy in platinum-sensitive recurrent ovarian cancer. hubs.li/Q03VT7Dw0 #cancer
The FDA has granted FTD to AVZO-103, an investigational Nectin4/TROP2 bispecific ADC, for adults with locally advanced or metastatic urothelial cancer following prior receipt of enfortumab vedotin. hubs.li/Q03VT5ZB0 #cancer #oncology
🏥 Real-World Data From IMS: Outpatient/Hybrid Step-Up Dosing in RRMM In episode 5 of this Between the Lines series, experts, Binod Dhakal, MD, MS, and Hans Lee, MD, reveal that new data shows that outpatient or hybrid dosing of Teclistamab can be safe, effective, and…
United States 趨勢
- 1. #DMDCHARITY2025 520K posts
- 2. #TusksUp N/A
- 3. #AEWDynamite 20.7K posts
- 4. #TheChallenge41 2,180 posts
- 5. Ryan Leonard N/A
- 6. #Survivor49 2,861 posts
- 7. Skyy Clark N/A
- 8. Jamal Murray 7,028 posts
- 9. Diddy 75K posts
- 10. Earl Campbell 2,163 posts
- 11. Claudio 29.6K posts
- 12. Yeremi N/A
- 13. Hannes Steinbach N/A
- 14. Steve Cropper 6,093 posts
- 15. seokjin 154K posts
- 16. Kevin Overton N/A
- 17. Klingberg N/A
- 18. Monkey Wards N/A
- 19. Ryan Nembhard 3,755 posts
- 20. Milo 12.7K posts
你可能會喜歡
-
The Cancer Letter
@TheCancerLetter -
ACS Journal Cancer
@JournalCancer -
Annals of Oncology
@Annals_Oncology -
OncLive.com
@OncLive -
Oncology Times
@OncologyTimes -
MD Anderson Cancer Center
@MDAndersonNews -
The Oncologist
@OncJournal -
The ASCO Post
@ASCOPost -
JNCI
@JNCI_Now -
Dana-Farber
@DanaFarber -
AACR
@AACR -
Oncology Tube
@oncologytube -
Duke Cancer
@DukeCancer -
Medscape Oncology
@MedscapeOnc -
Journal of Clinical Oncology
@JCO_ASCO
Something went wrong.
Something went wrong.